

Jasmin Beate Kuemmerle-Deschner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5442099/publications.pdf>

Version: 2024-02-01

68
papers

5,402
citations

94433

37
h-index

98798

67
g-index

72
all docs

72
docs citations

72
times ranked

4039
citing authors

#	ARTICLE	IF	CITATIONS
1	Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome. <i>New England Journal of Medicine</i> , 2009, 360, 2416-2425.	27.0	754
2	Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 678-685.	0.9	350
3	Classification criteria for autoinflammatory recurrent fevers. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1025-1032.	0.9	300
4	Adalimumab in the therapy of uveitis in childhood. <i>British Journal of Ophthalmology</i> , 2007, 91, 319-324.	3.9	263
5	Recommendations for the management of autoinflammatory diseases. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1636-1644.	0.9	239
6	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 799-805.	0.9	215
7	Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2095-2102.	0.9	182
8	Diagnostic criteria for cryopyrin-associated periodic syndrome (CAPS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 942-947.	0.9	175
9	Consensus classification criteria for paediatric Behçet's disease from a prospective observational cohort: PEDBD. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 958-964.	0.9	169
10	Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. <i>Arthritis and Rheumatism</i> , 2011, 63, 840-849.	6.7	147
11	Evidence-based recommendations for genetic diagnosis of familial Mediterranean fever. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 635-641.	0.9	145
12	Validation of the Auto-Inflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 2168-2173.	0.9	120
13	CAPS " pathogenesis, presentation and treatment of an autoinflammatory disease. <i>Seminars in Immunopathology</i> , 2015, 37, 377-385.	6.1	115
14	Canakinumab (ACZ885, a fully human IgG1 anti-IL-1 β mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). <i>Arthritis Research and Therapy</i> , 2011, 13, R34.	3.5	111
15	Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. <i>Arthritis Research and Therapy</i> , 2011, 13, R202.	3.5	106
16	The multifaceted presentation of chronic recurrent multifocal osteomyelitis: a series of 486 cases from the Eurofever international registry. <i>Rheumatology</i> , 2018, 57, 1203-1211.	1.9	105
17	International multi-centre study of pregnancy outcomes with interleukin-1 inhibitors. <i>Rheumatology</i> , 2017, 56, 2102-2108.	1.9	84
18	MRI Findings in Deep and Generalized Morphea (Localized Scleroderma). <i>American Journal of Roentgenology</i> , 2008, 190, 32-39.	2.2	82

#	ARTICLE	IF	CITATIONS
19	Inflammasome and cytokine blocking strategies in autoinflammatory disorders. <i>Clinical Immunology</i> , 2013, 147, 242-275.	3.2	75
20	International Retrospective Chart Review of Treatment Patterns in Severe Familial Mediterranean Fever, Tumor Necrosis Factor Receptor-Associated Periodic Syndrome, and Mevalonate Kinase Deficiency/Hyperimmunoglobulinemia D Syndrome. <i>Arthritis Care and Research</i> , 2017, 69, 578-586.	3.4	75
21	Registries in rheumatological and musculoskeletal conditions. Paediatric Behcet's disease: an international cohort study of 110 patients. One-year follow-up data. <i>Rheumatology</i> , 2011, 50, 184-188.	1.9	73
22	Impaired suppression of synovial fluid CD4+CD25 ^{hi} T cells from patients with juvenile idiopathic arthritis by CD4+CD25 ⁺ Treg cells. <i>Arthritis and Rheumatism</i> , 2011, 63, 3153-3162.	6.7	70
23	A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 309-314.	0.9	70
24	Comparison of treatment response, remission rate and drug adherence in polyarticular juvenile idiopathic arthritis patients treated with etanercept, adalimumab or tocilizumab. <i>Arthritis Research and Therapy</i> , 2016, 18, 272.	3.5	68
25	Development of the autoinflammatory disease damage index (ADDI). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 821-830.	0.9	68
26	Brief Report: Clinical and Molecular Phenotypes of Low-Penetrance Variants of <i>NLRP3</i> : Diagnostic and Therapeutic Challenges. <i>Arthritis and Rheumatology</i> , 2017, 69, 2233-2240.	5.6	68
27	Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. <i>Arthritis Research and Therapy</i> , 2013, 15, R64.	3.5	63
28	Hearing loss in Muckle-Wells syndrome. <i>Arthritis and Rheumatism</i> , 2013, 65, 824-831.	6.7	59
29	MRP8 and MRP14, phagocyte-specific danger signals, are sensitive biomarkers of disease activity in cryopyrin-associated periodic syndromes. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2075-2081.	0.9	57
30	Real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome. <i>Rheumatology</i> , 2016, 55, 689-696.	1.9	55
31	A web-based collection of genotype-phenotype associations in hereditary recurrent fevers from the Eurofever registry. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 167.	2.7	52
32	Safety of vaccinations in patients with cryopyrin-associated periodic syndromes: a prospective registry based study. <i>Rheumatology</i> , 2017, 56, 1484-1491.	1.9	52
33	NLRP3 E311K mutation in a large family with Muckle-Wells syndrome - description of a heterogeneous phenotype and response to treatment. <i>Arthritis Research and Therapy</i> , 2011, 13, R196.	3.5	51
34	Canakinumab in patients with cryopyrin-associated periodic syndrome: an update for clinicians. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2013, 5, 315-329.	2.7	46
35	B cell depletion for autoimmune diseases in paediatric patients. <i>Clinical Rheumatology</i> , 2011, 30, 87-97.	2.2	44
36	Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?. <i>Journal of Clinical Medicine</i> , 2021, 10, 128.	2.4	44

#	ARTICLE	IF	CITATIONS
37	Early detection of sensorineural hearing loss in Muckle-Wells-syndrome. <i>Pediatric Rheumatology</i> , 2015, 13, 43.	2.1	42
38	Brief Report: Severe Inflammation Following Vaccination Against <i>Streptococcus pneumoniae</i> in Patients With Cryopyrin-Associated Periodic Syndromes. <i>Arthritis and Rheumatology</i> , 2016, 68, 516-520.	5.6	42
39	Consensus protocols for the diagnosis and management of the hereditary autoinflammatory syndromes CAPS, TRAPS and MKD/HIDS: a German PRO-KIND initiative. <i>Pediatric Rheumatology</i> , 2020, 18, 17.	2.1	41
40	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 907-921.	0.9	38
41	Rapid and Sustained Long-Term Efficacy and Safety of Canakinumab in Patients With Cryopyrin-Associated Periodic Syndrome Ages Five Years and Younger. <i>Arthritis and Rheumatology</i> , 2019, 71, 1955-1963.	5.6	34
42	BTK operates a phospho-tyrosine switch to regulate NLRP3 inflammasome activity. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	33
43	A functional inflammasome activation assay differentiates patients with pathogenic NLRP3 mutations and symptomatic patients with low penetrance variants. <i>Clinical Immunology</i> , 2015, 157, 56-64.	3.2	32
44	In silico validation of the Autoinflammatory Disease Damage Index. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1599-1605.	0.9	27
45	New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. <i>Rheumatology</i> , 2020, 59, 3259-3263.	1.9	23
46	Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. <i>Rheumatology International</i> , 2007, 28, 153-156.	3.0	22
47	<i>NLRP3</i> A439V Mutation in a Large Family with Cryopyrin-associated Periodic Syndrome: Description of Ophthalmologic Symptoms in Correlation with Other Organ Symptoms. <i>Journal of Rheumatology</i> , 2016, 43, 1101-1106.	2.0	22
48	Efficacy and Safety of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis With and Without Fever at Baseline: Results From an Open-Label, Active-Treatment Extension Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 2147-2158.	5.6	21
49	Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome. <i>RMD Open</i> , 2020, 6, e001227.	3.8	21
50	Progressive familial hearing loss in Muckle-Wells syndrome. <i>Acta Oto-Laryngologica</i> , 2012, 132, 756-762.	0.9	19
51	Biologic Therapies in Polyarticular Juvenile Idiopathic Arthritis. Comparison of Long-Term Safety Data from the German BIKER Registry. <i>ACR Open Rheumatology</i> , 2020, 2, 37-47.	2.1	19
52	Challenges in Diagnosing Muckle-Wells Syndrome: Identifying Two Distinct Phenotypes. <i>Arthritis Care and Research</i> , 2014, 66, 765-772.	3.4	17
53	An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome. <i>Journal of Rheumatology</i> , 2019, 46, 429-436.	2.0	16
54	Induction of Myeloid-Derived Suppressor Cells in Cryopyrin-Associated Periodic Syndromes. <i>Journal of Innate Immunity</i> , 2016, 8, 493-506.	3.8	14

#	ARTICLE	IF	CITATIONS
55	Living with autoinflammatory diseases: identifying unmet needs of children, adolescents and adults. <i>Pediatric Rheumatology</i> , 2018, 16, 81.	2.1	14
56	Abatacept in difficult-to-treat juvenile idiopathic arthritis. <i>Biologics: Targets and Therapy</i> , 2009, 2, 865.	3.2	13
57	COVID-19 in Autoinflammatory Diseases with Immunosuppressive Treatment. <i>Journal of Clinical Medicine</i> , 2021, 10, 605.	2.4	13
58	Colchicine Effectiveness and Safety in Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis. <i>Frontiers in Pediatrics</i> , 2021, 9, 759664.	1.9	13
59	MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever. <i>Rheumatology</i> , 2022, 61, 3082-3092.	1.9	12
60	Methodological challenges in monitoring new treatments for rare diseases: lessons from the cryopyrin-associated periodic syndrome registry. <i>Orphanet Journal of Rare Diseases</i> , 2013, 8, 139.	2.7	11
61	Long-term safety and effectiveness of canakinumab therapy in patients with cryopyrin-associated periodic syndrome: results from the Î²-Confident Registry. <i>RMD Open</i> , 2021, 7, e001663.	3.8	11
62	Effective <i>ex vivo</i> inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3. <i>Rheumatology</i> , 2022, 61, e299-e313.	1.9	11
63	Management of Monogenic IL-1 Mediated Autoinflammatory Diseases in Childhood. <i>Frontiers in Immunology</i> , 2021, 12, 516427.	4.8	7
64	Colchicine “an effective treatment for children with a clinical diagnosis of autoinflammatory diseases without pathogenic gene variants. <i>Pediatric Rheumatology</i> , 2021, 19, 142.	2.1	5
65	Burden of illness in hereditary periodic fevers: a multinational observational patient diary study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 127, 26-34.	0.8	3
66	Cryopyrin-Associated Periodic Syndromes (CAPS). , 2019, , 347-365.		2
67	Comment on: real-life effectiveness of canakinumab in cryopyrin-associated periodic syndrome: reply. <i>Rheumatology</i> , 2016, 55, 1340.1-1341.	1.9	0
68	CAPS bei Kindern und Jugendlichen. <i>Springer Reference Medizin</i> , 2021, , 1-9.	0.0	0